Drug firm ZydusCadila has received final approval from the US health regulator to market Voriconazole tablets, used to treat fungal infections, in the American market.The ZydusCadila has received final approval from the US Food and Drug Administration (USFDA) to market Voriconazole tablets in strengths of 50 and 200 mg, CadilaHealhtcare said in a BSE filing.

The drug will be produced at the groups formulations manufacturing facility at Baddi (Himachal Pradesh).

Citing IMS data, the company said the estimated sales for Voriconazole tablets is USD 92.8 million as on March 2016.

Leave a Reply

Your email address will not be published. Required fields are marked *